Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

02-02-2026(Mon) 30-01-2026(Fri) 29-01-2026(Thu) 28-01-2026(Wed) 27-01-2026(Tue)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
12 Mar, 2026 (Thursday)

            
CGN NEW ENERGY(1811)
Analysis¡G
CGN New Energy¡¦s main power asset portfolio includes wind power, solar power, gas-fired, coal-fired, oil-fired, hydroelectric and biomass power generation projects in the electricity markets of China and South Korea, as well as one energy storage project. The Group¡¦s businesses in China are spread across 19 provinces, two autonomous regions and two municipalities, providing extensive geographic coverage and diversified business scope. Clean and renewable energy projects (namely wind power, solar power, gas-fired, hydroelectric and biomass projects) account for 85.7% of the Group¡¦s equity installed capacity; traditional energy projects (namely coal-fired and oil-fired projects) account for 14.3%. As of 30 June 2025, the Group¡¦s equity installed capacity totalled 10,501.4 MW, representing a year-on-year increase of 835 MW or 8.6%. Wind power and solar power together accounted for 67.6% of the Group¡¦s equity installed capacity, with wind power equity installed capacity at 4,436.4 MW and solar power equity installed capacity at 2,657.4 MW. The Group has further strengthened its solar business development, adding 786 MW of new equity installed capacity. The new capacity is mainly distributed as follows: (1) 350 MW Zhaoyuan offshore photovoltaic project in Shandong Province; (2) 230 MW Phase I Jianhu fishery-solar complementary photovoltaic project in Jiangsu Province; (3) 145 MW in Hebei Province; (4) 30 MW in Qinghai Province; (5) 27.6 MW in Zhejiang Province; and (6) 3.4 MW in Guangdong Province.As of 30 June 2025, the Group¡¦s major projects under construction in China are: (1) a 145 MW solar project in Hebei Province and (2) a 100 MW solar project in Hainan Province. Once these projects are commissioned, the Group¡¦s power generation capacity will be further enhanced.
In the energy storage sector, the Group is committed to fully leveraging the role of energy storage in the new-type power system, focusing on safety, efficiency and economics. It is concentrating on leading new energy storage technologies such as electrochemical storage, molten salt storage and compressed air energy storage, while conducting R&D and application demonstrations in key technologies for flow battery storage and thermal storage, to promote high-quality development of its energy storage business.
The Group¡¦s 200 MW/400 MWh shared energy storage power station project in Rudong, Jiangsu Province has successfully achieved full-capacity grid connection. This project is one of the largest shared energy storage stations in the East China region. Located in the Rudong Economic Development Zone of Nantong City, Jiangsu Province, the area features concentrated electricity load and strong, stable peak-shaving demand in the power market, making it highly suitable for shared energy storage development. The project has strengthened the power grid¡¦s flexible regulation capability, effectively improved renewable energy consumption, and will provide strong support for energy supply and grid stability in Jiangsu Province.
Looking ahead, the Group will drive innovation in green development models led by new energy, strengthen the construction of digital systems for green electricity operations and maintenance, seize the initiative in offshore wind and offshore solar innovation and development, and actively leverage the role of energy storage in the new power system. It will accelerate the commercialisation of achievements to serve the market, continuously create new growth drivers and competitive advantages, and promote the Company¡¦s high-quality development.(I do not hold the above stock.)
Strategy¡G
Buy-in Price: $2.80, Target Price: $3.10, Cut Loss Price: $2.65


CONSUN PHARMA(1681)
Analysis¡G
The Company mainly engaged in modern traditional Chinese patent medicines and simple preparations and medical imaging contrast agent. Niaoduqing Granules and Gdaptamide Injection are the two main products, and it also supplies a variety of other prescription drugs and OTC drugs. The Company's acquisition of Guangxi Yulin Pharmaceutical, a "Chinese time-honored brand" enterprise, has multiple OTC products with great development potential, including Zhenggu Shui, Shidu Qing, and Jigu Cao. Consun's revenue and profit increased in the first half of 2025: total revenue was 1.569 billion yuan, a yoy increase of 23.7%; The net profit attributable to the parent company was 498 million yuan, an increase of 24.6% yoy. GM climb to a new high of 77.1%. The growth in revenue and profit is mainly due to the increase in external customer revenue, and effective cost control has also driven profit growth. Under the situation of centralized procurement, the Company achieved price compensation based on quantity, maintaining its leading position in the market. In terms of market capitalization management, the company's continuous share repurchases demonstrate management's confidence in its intrinsic value. Recently included in the Hang Seng Composite Index, it is expected to further enhance liquidity and institutional attention.
Strategy¡G
Buy-in Price: $17.50, Target Price: $19.45, Cut Loss Price: $16.45



CHICMAX (2145.HK) Profit Alert Demonstrates Resilience, Multi-Brand Portfolio Entering Harvest Phase

Overview

CHICMAX is a research-driven, multi-brand leader in the cosmetics industry. Founded in 2002, the company owns three core brands¡XKANS, ONE LEAF, and Baby Elephant¡Xand has successfully established new growth drivers such as newpage and ARMIYO. It operates across four major segments: skincare, hair care, maternal and infant products, and cosmetics, with two self-built R&D centers and two supply chains worldwide. The flagship brand, KANS, achieved revenue exceeding RMB 5.5 billion in 2024, ranking as the No. 1 beauty brand on Douyin for the second consecutive year.

Performance review

The company has issued a positive profit alert, estimating that (i) in 2025, the company's revenue will be approximately RMB 9.1 billion to RMB 9.2 billion, representing a year-on-year increase of about 34.0% to 35.4%; and net profit will be approximately RMB 1.14 billion to RMB 1.16 billion, representing a year-on-year increase of about 41.9% to 44.4%. The increase in revenue and profit is primarily attributable to the successful implementation of the company's multi-brand and multi-category strategy, the continued revenue growth of its science-backed anti-aging skincare brand, KANS, and a significant year-on-year revenue increase from its Chinese efficacy skincare brand for infants and children, newpage.

In the first half of 2025, the company's revenue reached a new high of RMB 4.11 billion with a year-on-year increase of 17.3%; net profit attributable to the parent company amounting to RMB 556 million with a year-on-year increase of 34.7%; EPS was RMB 1.32 with a year-on-year increase of 30.7%. The company declared an interim dividend of RMB 0.5 per share, and the cumulative dividend payout since its listing has exceeded RMB 1.2 billion, maintaining a sustained high dividend payout ratio. For January 2026, the company's combined Gross Merchandise Volume (GMV) across the Douyin channel reached approximately RMB 660 million with a year-on-year increase of 9%, among which, KANS's GMV was approximately RMB 530 million with a year-on-year decrease of 3%; New Page's GMV was approximately RMB 70 million with a year-on-year increase of 120%; KYOCA and ATISER achieved a GMV of RMB 10 million respectively with rapid year-on-year growth; ARMIYO's GMV was approximately RMB 30 million with a year-on-year increase of 267%.

Figure 1¡GOperating income growth rate

"Figure

Resources: Annual report, Phillip Securities

Figure 2¡GDividend Payout Ratio

"Figure

Resources: Annual report, Phillip Securities

The flagship brand KANS's performance is eye-catching

According to Qingyan Intelligence, in 2025, the GMV of cosmetics on the Douyin channel grew by more than 16% year-on-year, with market share increasing by 2.6 percentage points. By brand nationality, domestic brands held a market share of 65.9%, occupying a dominant position. KANS, with over RMB 8 billion in GMV, continued to rank first among Douyin cosmetics brands, at a leading position, and maintained high growth momentum with over 20% growth rate. As of September 1, 2025, the cumulative sales of the hit product Polypeptide Collagen Softening exceeded 16.5 million sets, it is popular among consumers. The age of KANS' user portrait is mainly concentrated in the young group of 18-35 years old, accounting for as high as 73.09%, indicating that KANS' revenue growth is deeply bound with the young consumer group with skin care needs, and is expected to enjoy structural dividends. The main purchasers are concentrated in high-quality users in first - and second-tier cities (the top ten cities include Chongqing, Shanghai, Chengdu, Beijing, Guangzhou, Shenzhen, Suzhou, Xi'an, Dongguan and Hangzhou). We believe that users in first - and second-tier cities generally have higher incomes, stronger consumption resilience, and are relatively less price-sensitive, which may lay the foundation and channel cognition for KANS to launch high-end series in the future. In January 2026, the GMV of the beauty category on Douyin increased by 11.1% month-on-month, indicating that the festival scene has a significant pulling effect on cosmetic consumption. KANS topped the list again with a GMV of over RMB 300 million. To sum up, we believe that KANS has established a strong brand momentum, not only with a large market share (top of GMV), but also with a high-quality user structure, which can effectively resist the impact of competitive products and transcend the consumption cycle. In addition, in February this year, KANS' New One store officially opened. This is KANS' first directly operated offline concept store in its 23 years of establishment. We think it is a milestone step for the brand. KANS is currently the only domestic skin care brand in the core position of New One Stores. This move demonstrates KANS' strategic intention to enter the high-end market and compete with international first-line brands.

New Momentum Added to Multi-Brand Matrix

ATISER Accelerates Its Breakout
In July 2025, the company launched a new skincare brand, ATISER, focusing on skin radiance and anti-aging, translating clinical aesthetic outcomes into daily skincare routines. Its core product, the M22, was developed in collaboration with Shanghai Ninth People's Hospital. Infused with PDRN, it is hailed as a "fine line savior and brightening master," suitable for sensitive skin, delivering deep hydration, firming, and repair. The brand made its livestream debut on Douyin on the channel of Wei Xue, a top beauty influencer. According to Chanmama data, ATISER achieved a GMV of over RMB 6 million in July. By August, it accelerated its breakout, surpassing RMB 50 million in GMV. ATISER 's success is no accident¡Xit reflects the company¡¦s dual-engine strategy of "R&D + marketing." It demonstrates the company¡¦s ability to rapidly develop market-fit products based on consumer needs, while leveraging precise KOL collaborations to achieve brand synergy. This 0-to-1 rapid-launch capability is precisely the core competitive moat of CHICMAX in multi-brand operations.

China's first playful functional maternal & baby brand launched
Anpanman (baby and childcare), established in 2025, is the first playful functional maternal and baby brand in China under the Anpanman IP. The brand combines Anpanman's rich IP story elements and childlike designs to create a unique playful care experience for babies. Its product range includes face care, personal care, and home care series. Anpanman is a childhood memory spanning multiple generations. As of 2024, the total cumulative revenue from the Anpanman IP reached USD 60 billion, ranking sixth globally. We believe that Anpanman's deeply rooted image of "bravery, protection, warmth, and positivity" naturally aligns with the brand's philosophy of accompanying babies in their daily lives and helping them fearlessly navigate the outside world, creating a distinct co-branding differentiation in the market. The product packaging features the highly endearing Anpanman design, evoking instant emotional resonance among consumers through its adorable appeal. This effectively lowers the barrier to purchase decisions and enhances conversion rates at the point of sale.

Valuation and Investment Recommendation

According to data from the National Bureau of Statistics, the total retail sales of consumer goods in China exceeded RMB 50 trillion for the first time in 2025, reaching RMB 50,120.2 billion with a year-on-year increase of 3.7%. Consumption contributed 52% to economic growth, indicating stable expansion driven by policies aimed at boosting domestic demand. Retail sales of cosmetics in China also showed steady growth, increasing from RMB 204.94 billion in 2015 to RMB 435.65 billion in 2024, representing a CAGR of approximately 10.5%. Over the decade, cosmetics' share of the overall consumer market expanded from 1.5% in 2015 to 2.5% in 2024, confirming the increasingly critical role of cosmetic consumption in the structure of resident spending. Transitioning from reliance on a single brand to building a multi-brand matrix, the company's strategic transformation delivered results exceeding expectations in 2025, validating the feasibility of its new strategy. In the future, by replicating the successful paths of KANS and Newpage, more sub-brands are poised to become new engines for the company's growth. Amidst the rise of domestic brands and the consumption recovery, CHICMAX, already a frontrunner, is leveraging the core competitiveness of its multi-brand strategy to advance into a higher-tier market. We forecast the company's operating revenue to be RMB 9.15 billion, RMB 11.44 billion, and RMB 13.72 billion in 2025, 2026, and 2027 respectively, with EPS of RMB 2.89, 3.46, and 4.14, corresponding to P/E ratios of 17.7x, 14.8x, and 12.4x. We assign a target price of 78.64 HKD, based on 20x expected 2026 P/E, and upgrade the rating to "Buy." (Current price as of 12 Mar)

Risk factors

Downward macroeconomic situation, intensified industry competition, management changes, and new product promotion failing to meet expectations.

Financial

"Financial"
"PHILLIP

Current Price as of: 12 Mar
Exchange rate: HKD/RMB = 0.88
Source¡G PSHK Est.

Download PDF version




Recommendation on 12-3-2026
RecommendationBuy
Price on Recommendation Date$ 58.300
Suggested purchase priceN/A
Target Price$ 78.640
Writer Info
Margaret Li
(Analyst)
Tel: +852 2277 6535
Email:
margaretli@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2026 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]